Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia


ELİAÇIK E. , Isik A., Aydin C., ÜNER A. , AKSU S. , SAYINALP N. , ...Daha Fazla

HEMATOLOGY, cilt.20, sa.7, ss.392-396, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Konu: 7
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1179/1607845414y.0000000221
  • Dergi Adı: HEMATOLOGY
  • Sayfa Sayıları: ss.392-396

Özet

Objectives: The aim of this study was to assess bone marrow (BM) fibrosis and dysplasia in chronic myeloid leukemia (CML) patients receiving the first-generation tyrosine kinase inhibitor (TKI), imatinib, or secondgeneration TKIs, dasatinib, and nilotinib. We further investigated whether CML under TKI is associated with dysplastic BM changes during the clinicopathological course of the disease.